In a preliminary dose-ranging study, oral AT-0174 was determined to elevate tumour tryptophan and significantly attenuate tumour kynurenine in glioma cell-based xenograft malignancies that over-expressed IDO1 and TDO2. Here, IDO1 is linked to central nervous system cancer.